On Apr. 27, 2020, BioAegis Therapeutics announced it had published gene expression data in animal studies where recombinant human plasma gelsolin (rhu-pGSN) significantly increased survival in pneumonia due to severe influenza.

Importantly, the gene expression analysis of lung tissue showed that gelsolin treatment downregulated genes associated with the over-exuberant production of cytokines and other proinflammatory mediators often seen with infections such as COVID-19. Gelsolin-treated subjects have been shown to have less lung damage than those not treated.